Cardiol Therapeutics Inc. (CRDL) stock
CRDLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.86−0.02 (-2.28%)
Close on Nov 20, 2026Market cap $86.48MP/E –Yield –
Cardiol Therapeutics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -0.39 CAD. The highest annual figure on record is -0.39 CAD in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -0.39 CAD | – |
| FY2024 | Dec 31, 2024 | -0.51 CAD | – |
| FY2023 | Dec 31, 2023 | -0.44 CAD | – |
| FY2022 | Dec 31, 2022 | -0.49 CAD | – |
| FY2021 | Dec 31, 2021 | -0.73 CAD | – |
| FY2020 | Dec 31, 2020 | -0.69 CAD | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?